{"id":"maraviroc-darunavir-r","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Maraviroc is a CCR5 antagonist that prevents HIV from binding to and entering CD4+ T cells by blocking the CCR5 chemokine receptor on the cell surface. Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins necessary for infectious particle maturation, while ritonavir acts as a pharmacokinetic booster. Together, they provide complementary antiretroviral activity against HIV-1.","oneSentence":"This combination uses maraviroc to block HIV entry via the CCR5 co-receptor and darunavir/ritonavir to inhibit HIV protease, together suppressing viral replication through dual mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:25.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with CCR5-tropic virus"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT01348763","phase":"PHASE1","title":"The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-10","conditions":"HIV","enrollment":13},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01367210","phase":"PHASE4","title":"Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)","status":"TERMINATED","sponsor":"Catholic University of the Sacred Heart","startDate":"2011-06","conditions":"HIV Infection","enrollment":165},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Maraviroc, Darunavir/r","genericName":"Maraviroc, Darunavir/r","companyName":"Catholic University of the Sacred Heart","companyId":"catholic-university-of-the-sacred-heart","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses maraviroc to block HIV entry via CCR5 co-receptors and darunavir/ritonavir to inhibit HIV protease, together suppressing viral replication through dual mechanisms. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}